Clinical Trial

Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease

Name: Alpha-synuclein Education and Disclosure in Individuals With Preclinical and Symptomatic Lewy Body Disease — clinical trial record (NCT07646652)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

The goal of the study is to assess if learning one's Lewy Body Dementia (LBD) biomarker test result impacts longitudinal psychosocial and behavioral responses and to identify factors that moderate and mediate these outcomes.

Trial Details

NCT Number	NCT07646652
Lead Sponsor	Stanford University
Conditions	Lewy Body Disease
Enrollment	40 participants
Start Date	2026-11
Primary Completion	2030-11 (estimated)
Study Completion	2030-11 (estimated)
Updated on ClinicalTrials.gov	2026-06-15